Addendum: The value of comprehensive genomic sequencing to maximize the identification of clinically actionable alterations in advanced cancer patients: a case series

PDF  |  How to cite

Oncotarget. 2022; 13:1174-1174. https://doi.org/10.18632/oncotarget.28294

Metrics: PDF 480 views  |   ?  

Kevin Drenner1,*, Gargi D. Basu2,*, Laurie J. Goodman2, Audrey A. Ozols2, Janine R. LoBello2, Thomas Royce2, Michael S. Gordon3, Erkut H. Borazanci3, Margaux A. Steinbach3, Jeffrey Trent1 and Sunil Sharma1

1Translational Genomic Research Institute (Tgen), Phoenix, AZ 85004, USA
2Ashion Analytics, LLC, Phoenix, AZ 85004, USA
3HonorHealth Research Institute, Scottsdale, AZ 85258, USA
*These authors contributed equally to this work

Published: October 20, 2022

Copyright: © 2022 Drenner et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: The study, protocol # HRI-0029 is an IRB approved clinical study, WIRB # 20182804, and all patients signed informed consent to participate.

Original article: Oncotarget. 2021; 12:1836–1847. DOI: https://doi.org/10.18632/oncotarget.28046

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28294